Menu
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.32

€0.32

-
-
-
-

-

 
13.08.26 / Frankfurt WKN: A3D51F / Name: Thiogenesis Therapeutics Corp. / Stock / ? /

Thiogenesis Therapeutics Corp. Stock

Pros and Cons of Thiogenesis Therapeutics Corp. in the next few years

Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

Thiogenesis Appoints Dr. Gilad Aharon to its Board of DirectorsPhoto, wide shot, wide-angle lens,  Clinical research organization, sunset photo at golden hour, photo by Peter Lik: https://img.midjourneyapi.xyz/temp/02f7778c-d723-4fb3-bdef-fabb7e5fc9c8.png
Thiogenesis Appoints Dr. Gilad Aharon to its Board of Directors

SAN DIEGO, CA - June 17, 2026 - Thiogenesis Therapeutics, Corp. (TSXV: TTI; OTCQX: TTIPF) (“Thiogenesis” or the “Company”), a clinical-stage biotechnology company developing next-generation